https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-27 / Cancer Treat. Rev. 2015 Nov;41(9):742-53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-27 / Cancer Treat. Rev. 2015 Nov;41(9):742-532015-05-27 00:00:002019-02-15 09:18:02Local hyperthermia combined with radiotherapy and-/or chemotherapy: recent advances and promises for the future
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-27 / Onco Targets Ther 2015;8:1265-70
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-27 / Onco Targets Ther 2015;8:1265-702015-05-27 00:00:002015-05-27 00:00:00Hyperthermia combined with 5-fluorouracil promoted apoptosis and enhanced thermotolerance in human gastric cancer cell line SGC-7901
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-21 / World J. Gastroenterol. 2015 May;21(19):5778-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-21 / World J. Gastroenterol. 2015 May;21(19):5778-932015-05-21 00:00:002015-05-21 00:00:00Gastric cancer and the epoch of immunotherapy approaches
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-20 / Front Immunol 2015;6:243
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-20 / Front Immunol 2015;6:2432015-05-20 00:00:002019-02-15 08:45:05Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-19 / Radiother Oncol 2015 Nov;117(2):217-22
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-19 / Radiother Oncol 2015 Nov;117(2):217-222015-05-19 00:00:002015-05-19 00:00:00Local control rate after the combination of re-irradiation and hyperthermia for irresectable recurrent breast cancer: Results in 248 patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-18 / BJU Int. 2015 Sep;116(3):321-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-18 / BJU Int. 2015 Sep;116(3):321-92015-05-18 00:00:002019-02-15 08:45:12Advances in the understanding of cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-16 / Pharmacol. Ther. 2015 Sep;153:1-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-16 / Pharmacol. Ther. 2015 Sep;153:1-92015-05-16 00:00:002019-02-15 08:35:17Vaccine immunotherapy in lung cancer: Clinical experience and future directions
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-15 / Int J Hyperthermia 2015;31(6):609-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-15 / Int J Hyperthermia 2015;31(6):609-142015-05-15 00:00:002019-02-15 09:18:00Hyperthermia-related clinical trials on cancer treatment within the ClinicalTrials.gov registry
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-07 / Cell Death Dis 2015 May;6:e1758
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-07 / Cell Death Dis 2015 May;6:e17582015-05-07 00:00:002019-02-15 09:22:47IPS-1 differentially induces TRAIL, BCL2, BIRC3 and PRKCE in type I interferons-dependent and -independent anticancer activity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-01 / J. Immunother. 2015 May;38(4):155-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-01 / J. Immunother. 2015 May;38(4):155-642015-05-01 00:00:002019-02-15 08:45:07Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors
